## Valérie Devauchelle-Pensec

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10666628/publications.pdf

Version: 2024-02-01

92 papers 4,974 citations

76326 40 h-index 95266 68 g-index

98 all docs 98 docs citations 98 times ranked 3249 citing authors

#	Article	IF	CITATIONS
1	Treatment of Primary SjĶgren Syndrome With Rituximab. Annals of Internal Medicine, 2014, 160, 233-242.	3.9	325
2	Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis and Rheumatism, 2007, 57, 310-317.	6.7	280
3	Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 249.	7.4	241
4	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Annals of the Rheumatic Diseases, 2016, 75, 382-389.	0.9	225
5	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 1161-1168.	0.9	200
6	Contribution of salivary gland ultrasonography to the diagnosis of Sjögren's syndrome: Toward new diagnostic criteria?. Arthritis and Rheumatism, 2013, 65, 216-225.	6.7	188
7	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren's Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. PLoS ONE, 2013, 8, e59868.	2.5	147
8	Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: A systematic review. Autoimmunity Reviews, 2013, 12, 416-420.	5.8	146
9	B cells in Sjögren's syndrome: From pathophysiology to diagnosis and treatment. Journal of Autoimmunity, 2012, 39, 161-167.	6.5	145
10	Treatment of primary Sjögren syndrome. Nature Reviews Rheumatology, 2016, 12, 456-471.	8.0	137
11	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data SjA¶gren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050.	0.9	132
12	Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Annals of the Rheumatic Diseases, 2016, 75, 1506-1510.	0.9	124
13	ls salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review. Rheumatology, 2016, 55, 789-800.	1.9	120
14	The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Annals of the Rheumatic Diseases, 2013, 72, 665-671.	0.9	110
15	Salivary gland ultrasonography improves the diagnostic performance of the 2012 American College of Rheumatology classification criteria for Sjogren's syndrome. Rheumatology, 2014, 53, 1604-1607.	1.9	101
16	Epidemiology of neurological manifestations in Sj $\tilde{A}$ ¶gren's syndrome: data from the French ASSESS Cohort. RMD Open, 2016, 2, e000179.	3.8	88
17	Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability. RMD Open, 2017, 3, e000364.	3.8	87
18	Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2015, 67, 1623-1628.	5.6	85

#	Article	IF	CITATIONS
19	Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren's syndrome. Arthritis Research and Therapy, 2017, 19, 269.	3.5	77
20	Symptom-based stratification of patients with primary Sj $\tilde{A}$ ¶gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e85-e94.	3.9	76
21	Is periodontal disease mediated by salivary baff in sjögren's syndrome?. Arthritis and Rheumatism, 2005, 52, 2411-2414.	6.7	<b>7</b> 5
22	Neurological Disorders in Primary Sjögren's Syndrome. Autoimmune Diseases, 2012, 2012, 1-11.	0.6	72
23	Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome. Journal of Autoimmunity, 2016, 67, 102-110.	6.5	68
24	A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. Nature Communications, 2021, 12, 3523.	12.8	67
25	Severe Healthâ€Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patientâ€Reported Outcomes: Data From a Large Therapeutic Trial. Arthritis Care and Research, 2017, 69, 528-535.	3.4	65
26	Significance of B cells and B cell clonality in Sj $\tilde{A}$ ¶gren's syndrome. Arthritis and Rheumatism, 2010, 62, 2605-2610.	6.7	63
27	In Sjögren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmunity Reviews, 2012, 11, 252-258.	5.8	63
28	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 329-338.	0.9	61
29	Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjögren's syndrome. Joint Bone Spine, 2016, 83, 681-685.	1.6	58
30	The Fmsâ€like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome. Arthritis and Rheumatism, 2010, 62, 3447-3456.	6.7	55
31	Epidemiological profile and north–south gradient driving baseline systemic involvement of primary Sjögren's syndrome. Rheumatology, 2020, 59, 2350-2359.	1.9	54
32	ANCA-associated vasculitis in patients with primary Sjögren's syndrome: Detailed analysis of 7 new cases and systematic literature review. Autoimmunity Reviews, 2015, 14, 742-750.	5.8	52
33	Gene expression profile in the salivary glands of primary Sj $\tilde{A}$ ¶gren's syndrome patients before and after treatment with rituximab. Arthritis and Rheumatism, 2010, 62, 2262-2271.	6.7	49
34	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology, 2015, 54, 1699-1708.	1.9	49
35	The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2015, 49, 278-287.	6.5	49
36	Efficacy of Epratuzumab, an Antiâ€ <scp>CD</scp> 22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 763-773.	5.6	49

#	Article	IF	Citations
37	Reliability of histopathological salivary gland biopsy assessment in Sjogren's syndrome: a multicentre cohort study. Rheumatology, 2015, 54, 1056-1064.	1.9	47
38	Role of Fmsâ€like Tyrosine Kinase 3 Ligand as a Potential Biologic Marker of Lymphoma in Primary Sjögren's Syndrome. Arthritis and Rheumatism, 2013, 65, 3218-3227.	6.7	46
39	High-Grade Salivary-Cland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary SjÁ¶gren's Syndrome: Data from the TEARS Randomized Trial. PLoS ONE, 2016, 11, e0162787.	2.5	43
40	Level of agreement between 2002 American–European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren's syndrome and reasons for discrepancies. Arthritis Research and Therapy, 2014, 16, R74.	3.5	42
41	Ultrasound assessment of salivary glands in patients with primary SjĶgren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis. Biologics: Targets and Therapy, 2007, 1, 311-9.	3.2	42
42	ls early-onset primary Sjögren's syndrome a worse prognosis form of the disease?. Rheumatology, 2019, 58, 1163-1167.	1.9	39
43	Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren's syndrome. Arthritis Research and Therapy, 2014, 16, R15.	3.5	33
44	Can ARFI elastometry of the salivary glands contribute to the diagnosis of Sjögren's syndrome?. Joint Bone Spine, 2016, 83, 301-306.	1.6	33
45	A prospective evaluation of dental and periodontal status in patients with suspected Sjögren's syndrome. Joint Bone Spine, 2016, 83, 235-236.	1.6	33
46	Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2011, 29, 6-12.	0.8	33
47	Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. Arthritis Research and Therapy, 2018, 20, 11.	3.5	32
48	Time-course of ultrasound abnormalities of major salivary glands in suspected Sj $\tilde{A}$ ¶gren's syndrome. Joint Bone Spine, 2018, 85, 227-232.	1.6	29
49	Salivary gland ultrasonography in primary Sjögren's syndrome: opportunities and challenges. Rheumatology, 2019, , .	1.9	28
50	Ability of oblique foot radiographs to detect erosions in early arthritis: Results in the ESPOIR cohort. Arthritis and Rheumatism, 2008, 59, 1729-1734.	6.7	27
51	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2022, 81, 979-989.	0.9	27
52	Salivary gland ultrasound to diagnose Sjogren's syndrome: a claim to standardize the procedure. Rheumatology, 2015, 54, 199-200.	1.9	26
53	The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmunity Reviews, 2020, 19, 102670.	5.8	26
54	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. Rheumatology, 2021, 60, 1364-1375.	1.9	26

#	Article	IF	CITATIONS
55	Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatology, 2018, 57, 666-670.	1.9	25
56	Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica. Rheumatology, 2017, 56, 1401-1406.	1.9	24
57	Can artificial intelligence replace manual search for systematic literature? Review on cutaneous manifestations in primary Sjögren's syndrome. Rheumatology, 2020, 59, 811-819.	1.9	23
58	Is there specific neurological disorders of primary SjĶgren's syndrome?. Joint Bone Spine, 2015, 82, 86-89.	1.6	21
59	B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedure. Arthritis Research and Therapy, 2016, 18, 21.	3.5	20
60	Performance of hand radiographs in predicting the diagnosis in patients with early arthritis. Journal of Rheumatology, 2006, 33, 1511-5.	2.0	20
61	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. PLoS ONE, 2015, 10, e0133907.	2.5	19
62	Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary SjĶgren's syndrome?. Annals of the Rheumatic Diseases, 2016, 75, e33-e33.	0.9	19
63	The future of B cell-targeted therapies in Sjögren's syndrome. Immunotherapy, 2013, 5, 639-646.	2.0	18
64	Has the time come for biotherapies in giant cell arteritis and polymyalgia rheumatica?. Joint Bone Spine, 2016, 83, 471-472.	1.6	18
65	Diagnostic value of radiographs of the hands and feet in early rheumatoid arthritis. Joint Bone Spine, 2002, 69, 434-441.	1.6	17
66	Localized Myofascial Inflammation Revealed by Magnetic Resonance Imaging in Recent-onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy. Journal of Rheumatology, 2019, 46, 1619-1626.	2.0	17
67	Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis. RMD Open, 2016, 2, e000205.	3.8	15
68	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology, 2022, 62, 243-255.	1.9	12
69	Application of the OMERACT synovitis ultrasound scoring system in juvenile idiopathic arthritis: a multicenter reliability exercise. Rheumatology, 2021, 60, 3579-3587.	1.9	11
70	Healthy Patients Are Not the Best Controls for Microbiome-Based Clinical Studies: Example of Sjögren's Syndrome in a Systematic Review. Frontiers in Immunology, 2021, 12, 699011.	4.8	10
71	Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?. RMD Open, 2016, 2, e000305.	3.8	9
72	Assessment of major salivary gland size in primary Sjögren's syndrome: Comparison between clinical examination and ultrasonography. Joint Bone Spine, 2019, 86, 627-632.	1.6	9

#	Article	IF	Citations
73	Primary Sjögren's Syndrome Prevalence: What if Sjögren was Right After All? Comment on the Article by Maciel et al. Arthritis Care and Research, 2018, 70, 951-953.	3.4	8
74	What is the agreement between pathological features of parotid gland and labial salivary gland biopsies?. Annals of the Rheumatic Diseases, 2018, 77, e37-e37.	0.9	8
<b>7</b> 5	Seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome. Arthritis Research and Therapy, 2020, 22, 39.	3.5	8
76	Aortic involvement in giant cell arteritis. Joint Bone Spine, 2021, 88, 105045.	1.6	6
77	Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade. Rheumatology and Therapy, 2021, 8, 751-760.	2.3	6
78	Lymphopenia in early arthritis: Impact on diagnosis and 3-year outcomes (ESPOIR cohort). Joint Bone Spine, 2015, 82, 417-422.	1.6	5
79	Tocilizumab controls bone turnover in early polymyalgia rheumatica. Joint Bone Spine, 2021, 88, 105117.	1.6	5
80	Primary Sjögren's syndrome: new beginning for evidence-based trials. Lancet, The, 2022, 399, 121-122.	13.7	5
81	Salivary Glands and Periodontal Changes in a Population of Sjögren's and Sicca Syndrome Treated by Pilocarpine: A Pilot Study. Rheumatology and Therapy, 2021, 8, 219-231.	2.3	4
82	Treatment of Primary Sjögren Syndrome With Rituximab. Annals of Internal Medicine, 2014, 161, 377.	3.9	3
83	Pseudo-polyarthrite rhizomélique et artérite à cellules géantes en 2019. Revue Du Rhumatisme Monographies, 2019, 86, 199-206.	0.0	3
84	Is Tocilizumab as efficient as steroids early in polymyalgia rheumatica?. Seminars in Arthritis and Rheumatism, 2020, 50, 582.	3.4	2
85	Ultrasonography of the Salivary Gland in Primary Sjã¶gren Syndrome: Usefulness to Phenotype the Patients. Journal of Rheumatology, 2021, 48, 633-634.	2.0	2
86	Impact of the COVID-19 pandemic on therapeutic management of rheumatoid arthritis in Brittany (France). Joint Bone Spine, 2021, 88, 105179.	1.6	2
87	Joint involvement in Noonan syndrome. A retrospective paediatric descriptive study. Joint Bone Spine, 2022, 89, 105270.	1.6	2
88	Should we use ultrasonography in the clinic to detect pSS?. Nature Reviews Rheumatology, 2019, 15, 642-643.	8.0	1
89	A simplified radiographic score effectively predicts radiographic progression of early arthritis in a large nationwide French cohort. Rheumatology, 2020, 59, 1566-1573.	1.9	1
90	Évolution des anomalies observées à l'échographie des glandes salivaires principales dans les cas de suspicion de syndrome de Gougerot-Sjögren. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 465-470.	0.0	0

#	Article	IF	CITATIONS
91	Biopsies des glandes salivaires en rhumatologie. Revue Du Rhumatisme Monographies, 2020, 87, 184-188.	0.0	0
92	Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine, 2021, 88, 105221.	1.6	0